TrialFrontiers in immunology2023

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.

Jialei Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.